Impact of nonlinear interactions of pharmacokinetics and mics on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 38-45

  Chigutsa, Emmanuel ^a,e   Pasipanodya, Jotam G ^b   Visser, Marianne E ^c   Van Helden, Paul D ^d   Smith, Peter J ^a   Sirgel, Frederick A ^d   Gumbo, Tawa ^b   McIlleron, Helen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG EXPOSURE; FOLLOW UP; HUMAN; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PLASMA CONCENTRATION-TIME CURVE; SPUTUM CULTURE; STERILIZING ACTIVITY; TREATMENT OUTCOME; ADOLESCENT; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; DISINFECTION; DRUG ANTAGONISM; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSTRUMENT STERILIZATION; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SPUTUM; TUBERCULOSIS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; DISINFECTION; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; SPUTUM; STERILIZATION; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84920154923     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03931-14     Document Type: Article

References (47)

1. Jindani A, Doré CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167:1348-1354. http://dx.doi.org/10.1164/rccm.200210 -1125OC.
2. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062-2069.
3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society. 2003. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603-662. http://dx.doi.org/10.1164/rccm .167.4.603.
4. Canetti G, Grumbach F, Grosset J. 1960. Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid. Am Rev Respir Dis 82:295-313.
5. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223-1225. http://dx.doi.org/10.1164 /ajrccm/145.5.1223.
6. McCune RM, Feldmann FM, Lambert HP, McDermott W. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123:445-468.
7. McCune RM, Feldmann FM, McDermott W. 1966. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 123:469-486.
8. Mitchison DA. 1985. The action of antituberculosis drugs in shortcourse chemotherapy. Tubercle 66:219-225. http://dx.doi.org/10 .1016/0041-3879(85)90040-6.
9. Davies GR. 2010. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb) 90:171-176. http://dx.doi.org/10.1016/j.tube.2010.03.007.
10. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, Gatifloxacin for TB (OFLOTUB) Study Team. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12:128-138.
11. Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, van Helden P. 2008. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 12:792-798.
12. Chigutsa E, Patel K, Denti P, Visser M, Maartens G, Kirkpatrick CMJ, McIlleron H, Karlsson MO. 2013. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother 57:789-795. http://dx.doi.org/10.1128 /AAC.01876-12.
13. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
14. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197-3204. http://dx .doi.org/10.1128/AAC.01681-08.
15. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http: //dx.doi.org/10.1128/AAC.00414-06.
16. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-2124. http://dx.doi.org/10.1128/AAC.47.7.2118-2124.2003.
17. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009.Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis-Botswana. Clin Infect Dis 48:1685-1694. http: //dx.doi.org/10.1086/599040.
18. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T, Tuberculosis Trials Consortium. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40:1481-1491. http://dx.doi.org/10.1086 /429321.
19. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis /jit352.
20. Higgins JP. 2002. Nonlinear systems in medicine. Yale J Biol Med 75:247-260.
21. Salford Systems. 2001. MARS user guide. Salford Systems, San Diego, CA.
22. Lee YC, Lee TS, Lee WJ, Lin YC, Lee CK, Liew PL. 2012. Predictors of anemia after bariatric surgery using multivariate adaptive regression splines. Hepatogastroenterology 59:1378-1380. http://dx.doi.org/10 .5754/hge10155.
23. Koba M, Baczek T. 2013. The evaluation of multivariate adaptive regression splines for the prediction of antitumor activity of acridinone derivatives. Med Chem 9:1041-1050. http://dx.doi.org/10.2174/1573406411309080005.
24. Lin HY, Wang W, Liu YH, Soong SJ, York TP, Myers L, Hu JJ. 2008. Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP-SNP interactions and their application in prostate cancer. J Hum Genet 53:802-811. http://dx.doi.org/10.1007/s10038 -008-0313-z.
25. York TP, Eaves LJ, van den Oord EJ. 2006. Multivariate adaptive regression splines: a powerful method for detecting disease-risk relationship differences among subgroups. Stat Med 25:1355-1367. http://dx.doi.org /10.1002/sim.2292.
26. Visser ME, Grewal HM, Swart EC, Dhansay MA, Walzl G, Swanevelder S, Lombard C, Maartens G. 2010. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 93:93-100. http://dx.doi.org /10.3945/ajcn.110.001784.
27. WHO. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. WHO/CDS/TB/2003.313. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/HQ/2003/WHO-CDS-TB-2003. 313-eng.pdf.
28. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H. 2011. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 55:4122-4127. http://dx.doi.org/10 .1128/AAC.01833-10.
29. Chigutsa E, McIlleron H, Holford N. 2010. Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis, abstr. 1946. Population Approach Group Europe (PAGE), 8 to 11 June 2010, Berlin, Germany.
30. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2011. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 72:51-62. http://dx.doi .org/10.1111/j.1365-2125.2011.03940.x.
31. Jönsson S, Davidse A, Wilkins J, Van der Walt JS, Simonsson US, Karlsson MO, Smith P, McIlleron H. 2011. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother 55: 4230-4237. http://dx.doi.org/10.1128 /AAC.00274-11.
32. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 47: 1773-1780. http://dx.doi.org/10.1128/JCM.02501-08.
33. Friedman JH. 1991. Multivariate adaptive regression splines. Ann Statist 19:1-67. http://dx.doi.org/10.1214/aos/1176347963.
34. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 54:1484-1491. http://dx.doi.org/10.1128/AAC.01474-09.
35. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32:1002-1004. http://dx.doi.org/10.1128 /AAC.32.7.1002.
36. Conte JE, Jr, Golden JA, McIver M, Zurlinden E. 2006. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 28:114-121. http://dx .doi.org/10.1016/j.ijantimicag.2006.03.022.
37. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53:4178-4184. http://dx.doi .org/10.1128/AAC.00830-09.
38. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-551. http: //dx.doi.org/10.1128/AAC.36.3.548.
39. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. 2011. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampinresistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 55:5085-5089. http://dx.doi.org/10.1128/AAC.00269-11.
40. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230. http://dx.doi.org/10.1126/science.8284673.
41. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 6:1043-1047. http://dx.doi.org/10 .1038/79558.
42. Sloan DJ, Schipani A, Waterhouse D, Stone L, Mwandumba HC, Butterworth AE, Heyderman RS, Corbett EL, Khoo S, Davies G. 2014. Pharmacokinetic variability in TB therapy: associations with HIV and effect on outcome, abstr 106. Conference on Retroviruses and Opportunistic infections (CROI), 3 to 6 March 2014, Boston, MA.
43. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T, Tuberculosis Trials Consortium. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167:1341-1347. http://dx.doi.org/10.1164/rccm.200208-951OC.
44. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495 -200262150-00001.
45. Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69: 2420-2425. http://dx.doi.org/10.1093/jac/dku136.
46. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. 1993. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 147:958-961. http://dx.doi.org/10 .1164/ajrccm/147.4.958.
47. Senkoro M, Mfinanga SG, Mørkve O. 2010. Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania.BMCInfect Dis 10:210. http://dx.doi.org/10.1186/1471-2334-10-210.